Please log in to determine if you are eligible to purchase PT Programs.
MATURE B-CELL LEUKEMIA/LYMPHOMA MRD - FL8
FL8
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).

Procedure Challenges per Shipment Number of Shipments
Mature B‑cell leukemia/lymphoma minimal residual disease 3 Two shipments per year

Survey FL8 is intended for laboratories that currently or will begin to perform minimal residual disease (MRD) testing (rare event analysis) for mature B‑cell leukemia/lymphoma.


Program Information

  • Two 1.1‑mL specimens containing a cell line/whole blood mixture simulating mature B‑cell leukemia/lymphoma minimal residual disease with clinical history
  • One case with clinical history and gated dot plots

Shipping Schedule

  • Shipment A: February 9
  • Shipment B: August 3